Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC40 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Ascletis Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
ASC40 + bevacizumab is a **combination therapy** under clinical investigation for recurrent glioblastoma. ASC40 (code name TVB-2640) is an oral, selective, small molecule inhibitor of **fatty acid synthase (FASN)**, disrupting lipid metabolism essential for tumor cell survival and proliferation, while bevacizumab is a monoclonal antibody targeting **vascular endothelial growth factor A (VEGF-A)**, inhibiting angiogenesis. The combination aims to enhance anti-tumor efficacy by simultaneously disrupting tumor lipid metabolism and blocking tumor blood vessel formation. This therapy is being developed and trialed primarily by Ascletis Pharma, with clinical studies progressing through Phase III for recurrent glioblastoma patients. In clinical trials, ASC40 + bevacizumab demonstrated a favorable safety profile and improved progression-free survival and response rates compared to bevacizumab monotherapy[1][2][3][4][6][7].
- Other names
- ASC40 + bevacizumabTVB-2640 + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)FASN (Fatty acid synthase)
Beyond the preview
Go deeper on ASC40 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC40 + bevacizumab.